Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 1, 2007, Pages 71-75

  Ribeiro, Mariceli Araujo ^a,b   Paula, Claudete Rodrigues ^c  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Candida albicans; ERG11 gene; Fluconazole; Northern blot; Resistance

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CDR GENE; CELL GROWTH; DILUTION; ERG11 GENE; FUNGAL CELL; GENE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; INCUBATION TIME; INFLUENZA; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; UP-REGULATION;

EID: 33845387437     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.04.019     Document Type: Article

References (26)

1. Akins R.A. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43 (2005) 285-318
2. Albertson G.D., Niimi M., Cannon R.D., and Jenkinson H.F. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents. Chemother. 40 (1996) 2835-2841
3. Beck-Sague C.M., and Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. infect. Dis. 167 (1993) 1247-1251
4. Chau A.S., Mendrick C.A., Sabatelli F.J., Loebenrg D., and McNicholas P.M. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents. Chemother. 48 (2004) 2124-2131
5. Franz R., Kelly S.L., Lamb D.C., Kelly D.E., Ruhnke M., and Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents. Chemother. 42 (1998) 3065-3072
6. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanism of resistance and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12 (1999) 501-517
7. Henry K.W., Nickels J.T., and Edlind T.D. Upregulation of ERG genes in Candida albicans species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents. Chemother. 44 (2000) 2693-2700
8. Lee M., Williams L.E., Warnock D.W., and Arthington-Skaggs B.A. Drug resistance genes and trailing growth in Candida albicans isolates. J. Antimicrob. Chemother. 53 (2004) 217-224
9. Lyons C.N., and White T.C. Transcriptional analyses of antifungal drugs resistance in Candida albicans. Antimicrob. Agents. Chemother. 44 (2000) 2303-2596
10. Lopez-Ribot J.L., McAtee R.K., Perea S., Kirkpatrick W.R., Rinaldi M.G., and Patterson T.F. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob. Agents. Chemother. 43 (1999) 1621-1630
11. Maebeshi K., Niimi M., Kudoh M., Fischer F.J., Makimura K., Niimi K., Piper R.J., Uchida K., Arisawa M., Cannon R.D., and Yamaguchi H. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J. Antimicrob. Chemother. 47 (2001) 527-536
12. Marr K.A., Lyon C.N., Rustad T., Bowden R.A., and White T.C. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents. Chemother. 42 (1998) 2584-2589
13. Meunier F. Candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 438-447
14. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts-second edition: approved standard document M27-A2 (2002), NCCLS, Wayne (PA)
15. Perea S., Lopez-Ribot J.L., Kirkpatrick W.R., McAtee R.K., Santillan R.A., Martinez M., Calabrese D., Sanglard D., and Patterson T.F. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents. Chemother. 45 (2001) 2676-2684
16. Perea S., and Patterson T.F. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35 (2002) 1073-1080
17. Pfaller M. Epidemiology and control of fungal infections. Clin. Infect. Dis. 19 Suppl. 1 (1994) S8-S13
18. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Dib O.P., Fothergill A.W., Redding S.W., Rinaldi M.G., and Patterson T.F. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 174 (1996) 821-827
19. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24 (1997) 235-247
20. Ribeiro M.A., Paula C.R., Perfect J., and Cox G.M. Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. Med. Mycol. 43 (2005) 647-650
21. Roger P.D., and Barker K.S. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents. Chemother. 47 (2003) 1220-1227
22. Sanglard D., Kuchler K., Ischer F., Pagani J.L., Monod M., and Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents. Chemother. 39 (1995) 2378-2386
23. White T.C. Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents. Chemother. 41 (1997) 1482-1487
24. White T.C., Marr K.A., and Bowden R.A. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11 (1998) 382-402
25. White T.C., Holeman S., Dy F., Mirels L.F., and Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents. Chemother. 46 (2002) 1704-1713
26. Xu J., Ramos A.R., Vilgalys R., and Mitchell T.G. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J. Clin. Microbiol. 38 (2000) 1214-1220